Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 8/20 | 0.69 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.59 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662303 | 0.85 | CYP19A1 (0.73) | CYP19A1CYP17A1CYP26A1CYP3A4CYP11B1 | |
| SCHEMBL9190551 | 0.82 | CYP19A1 (0.50) | CYP19A1CYP17A1CYP26A1CYP3A4CYP11B1 | |
| Nitric Acid SCHEMBL8916910 | 0.82 | CYP17A1 (0.66) | CYP19A1CYP17A1CYP26A1CYP3A4CYP11B1 | |
| SCHEMBL4056684 | 0.81 | CYP19A1 (0.47) | CYP19A1CYP17A1CYP26A1CYP3A4KMT2A | |
| SCHEMBL4056672 | 0.81 | CYP19A1 (0.47) | CYP19A1CYP17A1CYP26A1CYP3A4KMT2A | |
| SCHEMBL4056679 | 0.81 | CYP19A1 (0.47) | CYP19A1CYP17A1CYP26A1CYP3A4KMT2A | |
| SCHEMBL9728006 | 0.77 | CYP17A1 (0.47) | CYP19A1CYP17A1CYP26A1CYP3A4CYP11B1 | |
| SCHEMBL4054853 | 0.77 | CYP17A1 (0.68) | CYP19A1CYP17A1CYP26A1CYP11B1CYP11B2 | |
| SCHEMBL6868753 | 0.77 | CYP19A1 (0.89) | CYP19A1CYP17A1CYP26A1CYP3A4CYP11B1 | |
| SCHEMBL19999188 | 0.75 | CYP19A1 (0.69) | CYP19A1CYP17A1CYP26A1CYP3A4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5612354-A | CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-18 | — | — | US | disclosed |
| US-5441954-A | Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells | JANSSEN PHARMACEUTICA N. V. (BE) | 1995-08-15 | — | — | US | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5268380-A | Therapy for keratinization in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-07 | — | — | US | disclosed |
| US-5185346-A | Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents | HANSSEN PHARMACEUTICA (BE) | 1993-02-09 | — | — | US | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |